8.40Open8.40Pre Close0 Volume7 Open Interest7.50Strike Price0.00Turnover8315.05%IV-30.72%PremiumJul 19, 2024Expiry Date15.45Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9621Delta0.0044Gamma1.45Leverage Ratio-21.4712Theta0.0000Rho1.39Eff Leverage0.0002Vega
Verona Pharma Stock Discussion
Stay calm, dont play in the hands of the shorts. Make sure your stock cannot be borrowed for shorts as well.
📌 This week’s PDUFAs:
$Merck & Co(MRK.US)$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma(VRNA.US)$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab(GMAB.US)$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co(MRK.US)$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...
$Harmony Biosciences(HRMY.US)$ : WAKIX (pitolisant)
$Bristol-Myers Squibb(BMY.US)$ : KRAZATI (Adagrasib) + Cetuximab
$argenx SE(ARGX.US)$ : VYVGART Hytrulo (Efgartigimod)
$Merck & Co(MRK.US)$ : Patritumab deruxtecan
$Verona Pharma(VRNA.US)$ : Ensifentrine (Nebulized)
$Rocket Pharmaceuticals(RCKT.US)$ : KRESLADI (Marnetegragene autotemcel)
This article does not even mention the upcoming approval date and is a sign of incomplete journalism.
No comment yet